Results 161 to 170 of about 196,069 (283)

Persistent headache and chronic daily headache after COVID-19: a prospective cohort study. [PDF]

Korean J Pain
Carvalho LCLS, Silva PAD, Rocha-Filho PAS.   +2 more
europepmc   +1 more source

Prescribing competence: The pros and cons of different methods for assessment

British Journal of Clinical Pharmacology, EarlyView.
Evaluating a medical graduate’s competence in rational prescribing is challenging. With the aim to guide and inspire teachers, this narrative review explores different methods that can be used to assess prescribing competence. Each method has its own advantages and disadvantages, and thus a mix of different assessment methods is needed throughout the ...
David J. Brinkman, Erik M. Donker, Jelle Tichelaar, on behalf of the CP4T programme   +3 more
wiley   +1 more source

Beyond right or wrong: How partial credit scoring on multiple‐choice questions improves student performance and assessment perceptions

British Journal of Clinical Pharmacology, EarlyView.
Aims In this study, we examined the effects of assigning partial credit to selected answer choices on student performance and perceptions in a pharmacology course using Type A multiple‐choice questions (MCQs). Methods Partial credit scoring was incorporated into quizzes and exams in a 10‐week pharmacology course for postbaccalaureate premedical ...
Stephen D. Schneid, Chris Armour, Katharina Brandl   +2 more
wiley   +1 more source

O050. Chronic daily headache and body mass index: a meta-analysis of observational studies. [PDF]

J Headache Pain, 2015
Tiseo C, Degan D, Ornello R, Gabriele A, Pistoia F, Carolei A, Sacco S.   +6 more
europepmc   +1 more source

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko, Titiaan E. Post, Pamela K. Strugala, Erica S. Klaassen, Linda E. Klumpers, Saco J. de Visser, Cristina Sempio, Jost Klawitter, Jules A. A. C. Heuberger, Geert J. Groeneveld   +9 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Chronic daily headache in children and adolescents [PDF]

Einstein (São Paulo), 2004
Mariana Machado Pereira, Deusvenir de Souza Carvalho   +1 more
doaj  

Chronic daily headache in Korea: prevalence, clinical characteristics, medical consultation and management. [PDF]

J Clin Neurol, 2014
Park JW, Moon HS, Kim JM, Lee KS, Chu MK.   +4 more
europepmc   +1 more source

Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh, Kate Hanrott, Olof Breuer, Johan Bylund, Björn Schultze, Virginia Norris   +5 more
wiley   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source